 FDA action approving narsoplimab in treatment of HSCT-TMA in Omeros upcoming PDUFA date has the potential to vault Omeros into multibagger territory overnight. Omeros narsoplimab in treatment of severely ill COVID-19 patients presents an interesting opportunity. 